PEDF-Derived Peptides for Multifactorial Dry Eye Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease are inadequate, with limited therapeutic options available that effectively address the multifactorial nature of the condition, leading to persistent ocular surface damage and inflammation.
Innovation Solution
Pharmaceutical compositions comprising PEDF-derived short peptides, specifically designed to prevent and treat dry eye syndrome by promoting tear production, maintaining goblet cell integrity, reducing inflammation, and alleviating oxidative stress, administered topically in the form of solutions, ointments, or gels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (artificial tears, anti-inflammatory drugs, analgesics) are used for dry eye disease, then some symptoms are alleviated, but the multifactorial nature of the condition remains unaddressed and ocular surface damage persists
Solution Approach 1:
The PEDF-derived peptide is designed to perform multiple therapeutic functions simultaneously: it acts as a growth factor to promote epithelial cell survival and proliferation, an anti-inflammatory agent to reduce cytokine production, and a cytoprotective molecule to prevent oxidative stress damage. This multi-functionality allows a single treatment to address the multifactorial nature of dry eye disease including tear film instability, inflammation, and ocular surface damage.
Solution Approach 2:
The invention utilizes a peptide derived from the larger PEDF protein through selective truncation and modification, creating a composite therapeutic agent that retains essential bioactive regions while removing inhibitory or less functional portions. The peptide sequence is optimized to maintain key functional domains for cell binding and signaling while improving stability and reducing immunogenicity compared to the full-length protein.
2Reliability
If the peptide sequence includes PDSP sequences (SLGAEQRTESIIHR or SLGAEHRTESVIHR), then certain biological activities are maintained, but the patent specifically excludes these sequences to achieve novel therapeutic effects
Solution Approach 1:
The invention extracts and utilizes specific functional regions from the PEDF protein while deliberately excluding the well-characterized PDSP sequences (residues 93-121). By taking out only the essential functional domains needed for cytoprotection and anti-inflammatory activity while removing sequences with known but insufficient therapeutic effects, the patent creates a novel peptide with improved therapeutic profile for dry eye disease.
Solution Approach 2:
The peptide sequence is modified by changing amino acid parameters at specific positions to optimize therapeutic activity. The patent specifies particular amino acid substitutions and deletions relative to the parent PEDF sequence and known PDSP variants, altering physical-chemical properties such as stability, solubility, and receptor binding characteristics to enhance therapeutic effectiveness for ocular surface protection.
Data Source
AI summary
A pharmaceutical composition for treating an ophthalmic disease in a subject includes a peptide and a pharmaceutically acceptable excipient, wherein the peptide contains the sequence of SEQ ID NO: 1: S-X-X-A-X-Q/H-X-X-X-X-I/V-I-X-R, wherein each X is independently any amino acid.